An observational study in Breast Cancer, sponsored by Royal Marsden NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-22.
Sponsored by Royal Marsden NHS Foundation Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Breast Neoplasms by Royal Marsden NHS Foundation Trust — 5 open to participants now, 9 under way, none of them phase 3. Breast Neoplasms · Royal Marsden NHS Foundation Trust.
Among the 42 studies in Breast Neoplasms by Royal Marsden NHS Foundation Trust, this one is the 4th largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2024, is one of 12 observational ones, and was the 41st registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →5 of the 42 studies in Breast Neoplasms by Royal Marsden NHS Foundation Trust are open now, in 2 countries. Recruiting first, the newest first:
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Royal Marsden NHS Foundation Trust · Sites in France, United Kingdom
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 3
First in 1997; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 62 across the 24 interventional studies, 150 across the 12 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Royal Marsden NHS Foundation Trust is the lead sponsor of 275 studies on the registry; 54 are open to participants now.
3 of the studies in Breast Neoplasms by Royal Marsden NHS Foundation Trust that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04920708Royal Marsden NHS Foundation TrustFulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression | 2027-06 |
| NCT04360941Royal Marsden NHS Foundation TrustPAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer | 2027-07-31 |
| NCT04985266Royal Marsden NHS Foundation TrustA Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 42 studies in Breast Neoplasms by Royal Marsden NHS Foundation Trust, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients who require a removal of a breast (mastectomy) for breast cancer or future risk reduction often have immediate breast reconstruction (IBR). This can be performed using either an implant or the patient's own body fat to recreate the breast shape.
Patients can find it difficult to imagine their own post-surgery appearance. Using 3D surface imaging (3D-SI) can change a patient's pictures to show them how they might look after surgery, known as a simulation. Some patients may find 3D-SI and simulation gives them confidence in their expectations and others may not feel it helps much.
This study will investigate the following 3 questions:
3D surface imaging may improve surgeon understanding of breast shape, prior to surgery. In cases where there is a high risk of breast cancer recurrence patients are offered radiotherapy to the breast, either before or after surgery. Radiotherapy has a negative impact on the reconstructed breast, and may cause it to shrink and change position but the effect of radiotherapy has never been accurately quantified. This study will be investigating the following:
Approximately 40% of all women diagnosed with breast cancer (BC) will require a mastectomy and a large proportion (60%) of these will choose to have an immediate breast reconstruction (IBR).
Patient satisfaction with physical appearance after completion of their BC treatment has a well-documented association not only with their psychological wellbeing but also improved quality of life. Due to advances in oncological therapies, BC patients now have excellent survival rates of 85% at five years and 75% at ten years meaning that more women survive to experience the long-term impact of surgical and radiotherapy treatments and highlights the importance of improving aesthetic outcome as a survivorship focus.
3D-surface imaging (3D-SI) and simulation is frequently used to demonstrate cosmetic breast augmentation outcomes in the private sector and is increasingly being used in breast cancer surgery.
Effective communication of the post-operative aesthetic outcome and the possible requirement of adjustment surgery to patients is a central part of the informed consent process. Women sometimes struggle to decide between breast-conserving treatment and mastectomy with or without reconstruction. Those that want reconstruction to have the option of using a silicone implant, or their own tissue, transplanted from the abdomen or inner thigh (an autologous flap). Consultations focus on the patient's desires and expectations, and the surgeon's explanation of what is technically possible, the benefits and compromises, until a mutual understanding is reached. This can however be challenging, particularly when attempting to predict the effects of adjuvant radiotherapy on the reconstructed breast. Traditionally, surgeons have used diagrams or 2D clinical photographs of other patients who have had surgery to demonstrate the predicted post-operative appearance. Many patients have reported that they find these methods unhelpful and confusing, as the wide variety of body habitus, breast shape, skin tone and surgical options mean that it is unlikely that a woman will see images adequately illustrating her own unique outcome.
The hypothesise that viewing 3D simulations of their own likely appearance after mastectomy and breast reconstruction will give women more confidence and certainty as they approach surgery. There are not yet in a position to use 3D-SI as a decision-support tool.
The overarching aim of this study is to evaluate the utility of 3D-SI in simulation and measurement of outcome of immediate breast reconstruction.
Hypothesis 1 - Impact of 3D Simulation on Shared Decision Making Women who see a simulation of their IBR outcome will have more confidence in their decision-making about IBR options.
Hypothesis 2 - Impact of 3D-SI on Elective Surgical Revision rate A better understanding of breast shape may reduce the need for elective surgical revisions such as volume-adjustment procedures (lipofilling or liposuction) in the reconstructed breast.
Hypothesis 3 - Impact of Radiotherapy on IBR The hypothesise that immediate breast reconstructions that receive radiotherapy undergo greater change in shape and position over time.
Patients considering breast reconstruction following mastectomy for cancer or risk reduction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
2D catalogue of photographs of other patients who have had surgery to demonstrate the predicted post-operative appearance
3D Simulation of patients own breast to show them how they might look after surgery
Difference in Visual Analogue Scale Score
Difference in mean visual analogue scale (VAS) for the question 'How confident is one in knowing how their breasts are likely to look after treatment?' VAS score is on a scale from 0-10 (0 indicates not at all confident and 10 indicates very confident)
Time frame: Preioperative/Periprocedural
Difference in decisional conflict scale score
Difference in Decisional Conflict Scale (DCS) score for women who see and do not see their simulated reconstruction
Time frame: Perioperative/Periprocedural
Comparison between 3D and SoC anthropometric measurements
Comparison between Crisalix and routine tape measure anthropometric measurements.The same unit of measurement will be used for the anthropometric distances (i.e.sternal notch to nippple, nipple to nipple, nipple to midline, nipple to lateral fold, nipple to inframammary fold and breast diameter) measured in cm for both 3D-SI and tape measurements
Time frame: Perioperative/Periprocedural
Thematic analysis of surgeons' experience
Thematic analysis of surgeons' experience
Time frame: 1 year
Evaluation of actual outcome against simulated appearance by panel assessment using a Likert scale
Evaluation of the actual outcome against the simulated appearance
Time frame: through study completion, an average of 1 year
Comparison of patient satisfaction with the breast, and with information given (BREAST-Q domains) by randomisation group
Comparison of patient satisfaction with the breast, and with information given (BREAST-Q domains) by randomisation group (3D simulation vs standard of care) at 1 and 2 years. To further undertake a panel assessment of 3D simulated outcomes and compare these to 2D images of actual post-operative appearance at 1 year after surgery. The panel will consist of consultant breast and plastic surgeons who will indicate likeness of simulated appearance to actual appearance on a Likert scale of 1-5 (score of 1 indicates that simulation is not at a similar to actual outcome and 5 indicates very similar appearance).
Time frame: through study completion, an average of 1 year
Using 3D-SI to classify breast shape
Using 3D-SI to classify breast shape
Time frame: through study completion, an average of 1 year
Impact of breast shape classification on elective secondary revisions (ESRs) and reconstructive outcomes
Impact of breast shape classification on elective secondary revisions (ESRs) and reconstructive outcomes. 3D-SI measurements (distances in cm and volume in cc) will be captured and using a principal component analysis different breast shape subgroups will be derived. Following this, to then compare breast shape type, primary surgery type (e.g. implant or autologous reconstruction) and whether the patient has had elective surgical revision. This will be an exploratory process to determine whether there is a relationship between breast shape and need for revision surgery. There is currently no existing tool to measure this. anthropometric measurements (sternal notch to nipple, nipple to nipple, nipple to inframammary fold, nipple to midline, nipple to lateral fold, breast diameter) are entered in cm and breast volume is entered in cc.
Time frame: through study completion, an average of 1 year
Documented relationship between donor tissue availability and breast volume
The intend to examine the relationship between the available abdominal donor tissue and required breast volume for patients undergoing autologous breast reconstruction. A comparison of the available abdominal tissue (measured in cc) using manual segmentation of the CT scan and the required breast volume measured in cc on the pre-operative 3D-SI measurement. We would like to investigate whether a greater degree of mismatch (abdominal volume in cc divided by breast volume in cc) is related to an increased likelihood of requiring revisional surgery.
Time frame: through study completion, an average of 1 year
Documented changes in shape of IBR with and without radiotherapy
volume Documented changes in shape of IBR with and without radiotherapy
Time frame: through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Sep 2026, 24 months after the start.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 24 months is below that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Royal Marsden NHS Foundation Trust →